2m 2m 2m 2m 2m 2m 2m
VAXCYTE (PCVX)
NASDAQ
$51.95-$0.16 (-0.32%)
Price as of Jun 23, 2026 4:10 PM EDT- $7.5BMarket Cap
- 56.72%1-Year Change
- BiotechnologyIndustry
VAXCYTE (PCVX)
$51.95-$0.16 (-0.32%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | 0 N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -794.3M +66.65% | -476.6M +43.42% | -332.3M +96.13% | -169.5M +116.11% | |
Depreciation and Amortization Expense | 16.4M +134.13% | 7.0M +121.89% | 3.2M +22.47% | 2.6M +43.17% | |
Total Operating Expenses | 923.7M +62.18% | 569.5M +21.69% | 468.0M +101.52% | 232.3M +124.03% | |
Operating Profit | -923.7M +62.18% | -569.5M +21.69% | -468.0M +101.52% | -232.3M +124.03% | |
Interest Income | 119.7M +8.84% | 110.0M +74.85% | 62.9M +652.84% | 8.4M +2,329.07% | |
Interest Expense | N/A N/A | N/A N/A | 0 +100.00% | -2,000 -71.43% | |
Interest Income and Expense and Net | 119.7M +8.84% | 110.0M +74.85% | 62.9M +653.02% | 8.4M +2,378.93% | |
Total Nonoperating Income and Expense | 157.0M +48.69% | 105.6M +60.58% | 65.8M +649.91% | 8.8M +144.11% | |
Income before Taxes | -923.7M +62.18% | -569.5M +21.69% | -468.0M +101.52% | -232.3M +124.03% | |
Income Taxes | 0 N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | 0 N/A | 0 -100.00% | 213,000 N/A | |
Net Income | -766.6M +65.25% | -463.9M +15.33% | -402.3M +80.00% | -223.5M +123.31% | |
Net Income from Continuing Operations Applicable to Common | -766.6M +65.25% | -463.9M +15.33% | -402.3M +80.00% | -223.5M +123.31% | |
Basic EPS and Net Income | -5.63 +48.16% | -3.80 -8.21% | -4.14 +20.35% | -3.44 +78.24% | |
Diluted EPS and Net Income | -5.63 +48.16% | -3.80 -8.21% | -4.14 +20.35% | -3.44 +78.24% | |
Basic Weighted Average Shares | 136.1M +11.55% | 122.0M +25.57% | 97.2M +49.75% | 64.9M +24.95% | |
Diluted Weighted Average Shares | 136.1M +11.55% | 122.0M +25.57% | 97.2M +49.75% | 64.9M +24.95% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 174.0M -55.15% | 387.9M -2.41% | 397.5M -52.38% | 834.7M +1,109.91% | |
Short-Term Investments | 1.4B +2.04% | 1.4B +99.09% | 682.8M +605.94% | 96.7M -45.35% | |
Cash and Cash Equivalents and Short-Term Investments | 1.6B -10.66% | 1.7B +61.74% | 1.1B +15.98% | 931.4M +278.65% | |
Total Current Assets | 1.6B -8.98% | 1.8B +63.14% | 1.1B +16.27% | 942.6M +267.69% | |
Accumulated Depreciation | 32.8M +101.36% | 16.3M +75.52% | 9.3M +51.58% | 6.1M +72.41% | |
Property and Plant and Equipment and Net | 257.4M +29.96% | 198.0M +148.72% | 79.6M +668.59% | 10.4M +30.25% | |
Total Long-Term Assets | 1.4B -20.19% | 1.7B +452.42% | 312.0M +390.33% | 63.6M -6.42% | |
Total Assets | 3.0B -14.48% | 3.5B +149.40% | 1.4B +39.93% | 1.0B +210.23% | |
Income Taxes Payable | 4.7M N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 205.8M +46.78% | 140.2M -3.55% | 145.3M +258.64% | 40.5M +41.12% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 100,000 0.00% | 100,000 N/A | 0 -100.00% | 9,000 -90.62% | |
Total Liabilities | 317.2M +54.36% | 205.5M +22.72% | 167.4M +218.56% | 52.6M +30.37% | |
Retained Earnings | -2.2B +55.22% | -1.4B +50.19% | -924.4M +77.04% | -522.1M +74.83% | |
Total Stockholders Equity | 2.7B -18.76% | 3.3B +166.50% | 1.2B +30.08% | 953.6M +235.76% | |
Total Shares Outstanding | 131.1M +4.94% | 124.9M +30.96% | 95.4M +20.00% | 79.5M +49.85% | |
Cash Flow | |||||
Cash from Operating Activities | -655.6M +44.84% | -452.6M +52.51% | -296.8M +73.97% | -170.6M +40.53% | |
Capital Expenditures | 13.7M -38.85% | 22.4M +39.63% | 16.1M +174.66% | 5.8M -10.79% | |
Cash from Investing Activities | 437.4M +121.81% | -2.0B +159.36% | -773.3M -1,136.82% | 74.6M +135.13% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 2.0M -99.92% | 2.4B +282.69% | 639.8M -25.74% | 861.5M +4,741.24% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -23.54% +24.79% | -18.86% -43.40% | -33.33% -0.80% | -33.59% +20.37% | |
Return on Equity | -25.59% +25.39% | -20.41% -44.34% | -36.67% +1.53% | -36.11% +13.65% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 7.91 -37.99% | 12.75 +69.15% | 7.54 -67.58% | 23.26 +160.54% | |
Cash Ratio | 0.85 -69.44% | 2.77 +1.18% | 2.73 -86.72% | 20.60 +757.35% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow